Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2002

View Archived Issues

New licensing agreement signed by JT for JTE-522

Systemic antitumor response follows s.c. or intrahepatic suicide cell-based vaccination

New antedrugs with therapeutic potential in psoriasis

Potential therapeutic agent for Chagas' disease enters development

Natural plant pigment exerts chemopreventive effects in mouse colon cancer model

Wyeth-Ayerst engineers new transgenic rat model for ALS research

Vernalis and Roche collaborate on diabetes drug development

Morphine-sparing analgesic effects demonstrated for valdecoxib in knee replacement surgery trial

Shareholder approval for Millennium and Cor Therapeutics merger

aaiPharma licenses rights to Tanatril in U.S.

FDA approves BioStratum's IND for antiangiogenesis agent

CCL's Aspirair technology incorporated into Vectura business

AVI BioPharma licenses calicivirus patent

Patient enrollment begins for ALVAC-CEA/B7.1 study in colorectal cancer

Discovery Therapeutics changes name to Aderis

TAK-457 may be more effective than amphotericin B as Rx for invasive pulmonary aspergillosis

Preparation and use of new glucagon receptor antagonists/inverse agonists patented by Novo Nordisk

Pfizer synthesizes JAK3 inhibitors potentially useful as immunosuppressants

Recent patent discloses NMDA NR2B antagonists designed at Merck

Novel factor Xa inhibitors for treatment of thromboembolic disorders

Eisai seeks FDA clearance for new indication of Aciphex/Pariet

Tripeptide prodrugs of therapeutic agents with improved toxicity profile prepared at Corixa

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...